Divergent H7 immunogens offer protection from H7N9 virus challenge

Journal of Virology

Volumn 88, Issue 8, 2014, Pages 3976-3985

  Krammer, Florian ^a   Albrecht, Randy A ^a   Tan, Gene S ^a   Margine, Irina ^a   Hai, Rong ^a   Schmolke, Mirco ^a   Runstadler, Jonathan ^b   Andrews, Sarah F ^c   Wilson, Patrick C ^c   Cox, Rebecca J ^d,e   Treanor, John J ^f   García Sastre, Adolfo ^a   Palese, Peter ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF BERGEN   (Norway)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ 7 VACCINE; MEDIMMUNE; UNCLASSIFIED DRUG; VIRUS SIALIDASE; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CROSS REACTION; DOG; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; EMBRYO; ENZYME INHIBITION; HUMAN; HUMAN CELL; INFLUENZA A; INFLUENZA VACCINATION; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H7N9; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; VACCINATION;

EID: 84896979547     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03095-13     Document Type: Article

References (40)

1. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu H, Xu K, Xu X, Lu H, Zhu W, Gao Z, Xiang N, Shen Y, He Z, Gu Y, Zhang Z, Yang Y, Zhao X, Zhou L, Li X, Zou S, Zhang Y, Yang L, Guo J, Dong J, Li Q, Dong L, Zhu Y, Bai T, Wang S, Hao P, Yang W, Han J, Yu H, Li D, Gao GF, Wu G, Wang Y, Yuan Z, Shu Y. 2013. Human infection with a novel avian-origin influenza A (H7N9) virus. N. Engl. J. Med. 368:1888-1897. http://dx.doi.org/10.1056/NEJMoa1304459.
2. CDC. 2013. Emergence of avian influenza A(H7N9) virus causing severe human illness-China, February-April 2013. MMWR Morb. Mortal. Wkly. Rep. 62:366-371. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6218a6.htm.
3. Yu H, Cowling BJ, Feng L, Lau EH, Liao Q, Tsang TK, Peng Z, Wu P, Liu F, Fang VJ, Zhang H, Li M, Zeng L, Xu Z, Li Z, Luo H, Li Q, Feng Z, Cao B, Yang W, Wu JT, Wang Y, Leung GM. 2013. Human infection with avian influenza A H7N9 virus: an assessment of clinical severity. Lancet 382:138-145. http://dx.doi.org/10.1016/S0140-6736(13)61207-6.
4. Hu Y, Lu S, Song Z, Wang W, Hao P, Li J, Zhang X, Yen HL, Shi B, Li T, Guan W, Xu L, Liu Y, Wang S, Tian D, Zhu Z, He J, Huang K, Chen H, Zheng L, Li X, Ping J, Kang B, Xi X, Zha L, Li Y, Zhang Z, Peiris M, Yuan Z. 2013. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 381:2273-2279. http://dx.doi.org/10.1016/S0140-6736(13)61125-3.
5. Hai R, Schmolke M, Leyva-Grado VH, Thangavel RR, Margine I, Jaffe EL, Krammer F, Solórzano A, García-Sastre A, Palese P, Bouvier NM. 2013. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nat. Commun. 4:2854. http://dx.doi.org/10.1038/ncomms3854.
6. Ip DK, Liao Q, Wu P, Gao Z, Cao B, Feng L, Xu X, Jiang H, Li M, Bao J, Zheng J, Zhang Q, Chang Z, Li Y, Yu J, Liu F, Ni MY, Wu JT, Cowling BJ, Yang W, Leung GM, Yu H. 2013. Detection of mild to moderate influenza A/H7N9 infection by China's national sentinel surveillance system for influenza-like illness: case series. BMJ 346:f3693. http://dx.doi.org/10.1136/bmj.f3693.
7. Xiong X, Martin SR, Haire LF, Wharton SA, Daniels RS, Bennett MS, McCauley JW, Collins PJ, Walker PA, Skehel JJ, Gamblin SJ. 2013. Receptor binding by an H7N9 influenza virus from humans. Nature 499: 496-499. http://dx.doi.org/10.1038/nature12372.
8. Belser JA, Gustin KM, Pearce MB, Maines TR, Zeng H, Pappas C, Sun X, Carney PJ, Villanueva JM, Stevens J, Katz JM, Tumpey TM. 2013. Pathogenesis and transmission of avian influenza A (H7N9) virus in ferrets and mice. Nature 501:556-559. http://dx.doi.org/10.1038/nature12391.
9. Watanabe T, Kiso M, Fukuyama S, Nakajima N, Imai M, Yamada S, Murakami S, Yamayoshi S, Iwatsuki-Horimoto K, Sakoda Y, Takashita E, McBride R, Noda T, Hatta M, Imai H, Zhao D, Kishida N, Shirakura M, de Vries RP, Shichinohe S, Okamatsu M, Tamura T, Tomita Y, Fujimoto N, Goto K, Katsura H, Kawakami E, Ishikawa I, Watanabe S, Ito M, Sakai-Tagawa Y, Sugita Y, Uraki R, Yamaji R, Eisfeld AJ, Zhong G, Fan S, Ping J, Maher EA, Hanson A, Uchida Y, Saito T, Ozawa M, Neumann G, Kida H, Odagiri T, Paulson JC, Hasegawa H, Tashiro M, Kawaoka Y. 2013. Characterization of H7N9 influenza A viruses isolated from humans. Nature 501:551-555. http://dx.doi.org/10.1038/nature12392.
10. Ramos I, Krammer F, Hai R, Aguilera D, Bernal-Rubio D, Steel J, García-Sastre A, Fernandez-Sesma A. 2013. H7N9 influenza viruses interact preferentially with α2,3-linked sialic acids and bind weakly to α2,6-linked sialic acids. J. Gen. Virol. 94:2417-2423. http://dx.doi.org/10.1099/vir.0.056184-0.
11. Xu R, de Vries RP, Zhu X, Nycholat CM, McBride R, Yu W, Paulson JC, Wilson IA. 2013. Preferential recognition of avian-like receptors in human influenza A H7N9 viruses. Science 342:1230-1235. http://dx.doi.org/10.1126/science.1243761.
12. Cox RJ, Madhun AS, Hauge S, Sjursen H, Major D, Kuhne M, Höschler K, Saville M, Vogel FR, Barclay W, Donatelli I, Zambon M, Wood J, Haaheim LR. 2009. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 27:1889-1897. http://dx.doi.org/10.1016/j.vaccine.2009.01.116.
13. Couch RB, Patel SM, Wade-Bowers CL, Niño D. 2012. A randomized clinical trial of an inactivated avian influenza A(H7N7) vaccine. PLoS One 7:e49704. http://dx.doi.org/10.1371/journal.pone.0049704.
14. Hai R, Krammer F, Tan GS, Pica N, Eggink D, Maamary J, Margine I, Albrecht RA, Palese P. 2012. Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J. Virol. 86:5774-5781. http://dx.doi.org/10.1128/JVI.00137-12.
15. Krammer F, Margine I, Tan GS, Pica N, Krause JC, Palese P. 2012. A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates. PLoS One 7:e43603. http://dx.doi.org/10.1371/journal.pone.0043603.
16. Margine I, Palese P, Krammer F. 2013. Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. J. Vis. Exp. 2013: e51112. http://dx.doi.org/10.3791/51112.
17. Wang S, Taaffe J, Parker C, Solórzano A, Cao H, García-Sastre A, Lu S. 2006. Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. J. Virol. 80:11628-11637. http://dx.doi.org/10.1128/JVI.01065-06.
18. Bentebibel SE, Lopez S, Obermoser G, Schmitt N, Mueller C, Harrod C, Flano E, Mejias A, Albrecht RA, Blankenship D, Xu H, Pascual V, Banchereau J, Garcia-Sastre A, Palucka AK, Ramilo O, Ueno H. 2013. Induction of ICOS+CXCR3+CXCR5+THcells correlates with antibody responses to influenza vaccination. Sci. Transl. Med. 5:176ra32. http://dx.doi.org/10.1126/scitranslmed.3005191.
19. De Groot AS, Ardito M, Terry F, Levitz L, Ross TM, Moise L, Martin W. 2013. Low immunogenicity predicted for emerging avian-origin H7N9: implication for influenza vaccine design. Hum. Vaccin. Immunother. 9:950-956. http://dx.doi.org/10.4161/hv.24939.
20. GoffPH, Krammer F, Hai R, Seibert CW, Margine I, García-Sastre A, Palese P. 2013. Induction of cross-reactive antibodies to novel H7N9 influenza virus by recombinant Newcastle disease virus expressing a North American lineage H7 subtype hemagglutinin. J. Virol. 87:8235-8240. http://dx.doi.org/10.1128/JVI.01085-13.
21. Abbas MA, Spackman E, Fouchier R, Smith D, Ahmed Z, Siddique N, Sarmento L, Naeem K, McKinley ET, Hameed A, Rehmani S, Swayne DE. 2011. H7 avian influenza virus vaccines protect chickens against challenge with antigenically diverse isolates. Vaccine 29:7424-7429. http://dx.doi.org/10.1016/j.vaccine.2011.07.064.
22. US Food and Drug Administration. 2013. FDA approves new seasonal influenza vaccine made using novel technology. US Food and Drug Administration, Washington, DC. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm335891.htm.
23. Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, Lee JH, Metlagel Z, Bujny MV, Jongeneelen M, van der Vlugt R, Lamrani M, Korse HJ, Geelen E, Sahin Ö, Sieuwerts M, BrakenhoffJP, Vogels R, Li OT, Poon LL, Peiris M, Koudstaal W, Ward AB, Wilson IA, Goudsmit J, Friesen RH. 2012. Highly conserved protective epitopes on influenza B viruses. Science 337:1343-1348. http://dx.doi.org/10.1126/science.1222908.
24. Xu Q, Chen Z, Cheng X, Xu L, Jin H. 2013. Evaluation of live attenuated H7N3 and H7N7 vaccine viruses for their receptor binding preferences, immunogenicity in ferrets and cross reactivity to the novel H7N9 virus. PLoS One 8:e76884. http://dx.doi.org/10.1371/journal.pone.0076884.
25. Li Y, Myers JL, Bostick DL, Sullivan CB, Madara J, Linderman SL, Liu Q, Carter DM, Wrammert J, Esposito S, Principi N, Plotkin JB, Ross TM, Ahmed R, Wilson PC, Hensley SE. 2013. Immune history shapes specificity of pandemic H1N1 influenza antibody responses. J. Exp. Med. 210:1493-1500. http://dx.doi.org/10.1084/jem.20130212.
26. Tweed SA, Skowronski DM, David ST, Larder A, Petric M, Lees W, Li Y, Katz J, Krajden M, Tellier R, Halpert C, Hirst M, Astell C, Lawrence D, Mak A. 2004. Human illness from avian influenza H7N3, British Columbia. Emerg. Infect. Dis. 10:2196-2199. http://dx.doi.org/10.3201/eid1012.040961.
27. Fouchier RA, Schneeberger PM, Rozendaal FW, Broekman JM, Kemink SA, Munster V, Kuiken T, Rimmelzwaan GF, Schutten M, Van Doornum GJ, Koch G, Bosman A, Koopmans M, Osterhaus AD. 2004. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc. Natl. Acad. Sci. U. S. A. 101:1356-1361. http://dx.doi.org/10.1073/pnas.0308352100.
28. CDC. 2012. Notes from the field: highly pathogenic avian influenza A (H7N3) virus infection in two poultry workers-Jalisco, Mexico, July 2012. MMWR Morb. Mortal. Wkly. Rep. 61:726-727. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6136a4.htm.
29. Belser JA, Bridges CB, Katz JM, Tumpey TM. 2009. Past, present, and possible future human infection with influenza virus A subtype H7. Emerg. Infect. Dis. 15:859-865. http://dx.doi.org/10.3201/eid1506.090072.
30. Morens DM, Taubenberger JK, Fauci AS. 2013. H7N9 avian influenza A virus and the perpetual challenge of potential human pandemicity. mBio 4(4):e00445-13. http://dx.doi.org/10.1128/mBio.00445-13.
31. Manicassamy B, Medina RA, Hai R, Tsibane T, Stertz S, Nistal-Villán E, Palese P, Basler CF, García-Sastre A. 2010. Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog. 6:e1000745. http://dx.doi.org/10.1371/journal.ppat.1000745.
32. Skowronski D, Janjua N, Kwindt T, De Serres G. 2013. Virus-host interactions and the unusual age and sex distribution of human cases of influenza A(H7N9) in China, April 2013. Euro Surveill. 18(17):20465. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20465.
33. van de Sandt CE, Kreijtz JH, de Mutsert G, Geelhoed-Mieras MM, Hillaire ML, Vogelzang-van Trierum SE, Osterhaus AD, Fouchier RA, Rimmelzwaan GF. 2014. Human cytotoxic T lymphocytes directed to seasonal influenza A viruses cross-react with the newly emerging H7N9 virus. J. Virol. 88:1684-1693. http://dx.doi.org/10.1128/JVI.02843-13.
34. Krammer F, Cox RJ. 2013. The emergence of H7N9 viruses: a chance to redefine correlates of protection for influenza virus vaccines. Expert Rev. Vaccines 12:1369-1372. http://dx.doi.org/10.1586/14760584.2013.850036.
35. Cox RJ, Major D, Hauge S, Madhun AS, Brokstad KA, Kuhne M, Smith J, Vogel FR, Zambon M, Haaheim LR, Wood J. 2009. A cell-based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models. Influenza Other Respir. Viruses 3:107-117. http://dx.doi.org/10.1111/j.1750-2659.2009.00082.x.
36. Smith GE, Flyer DC, Raghunandan R, Liu Y, Wei Z, Wu Y, Kpamegan E, Courbron D, Fries LF, Glenn GM. 2013. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. Vaccine 31:4305-4313. http://dx.doi.org/10.1016/j.vaccine.2013.07.043.
37. Rudenko L, Isakova-Sivak I, Donina S. 2013. H7N3 live attenuated influenza vaccine has a potential to protect against new H7N9 avian influenza virus. Vaccine 31:4702-4705. http://dx.doi.org/10.1016/j.vaccine.2013.08.040.
38. Rudenko L, Isakova-Sivak I, Rekstin A. 2014. H7N9: can H7N3 liveattenuated influenza vaccine be used at the early stage of the pandemic? Expert Rev. Vaccines 13:1-4. http://dx.doi.org/10.1586/14760584.2014.864564.
39. Klausberger M, Wilde M, Palmberger D, Hai R, Albrecht RA, Margine I, Hirsh A, García-Sastre A, Grabherr R, Krammer F. 2014. One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge. Vaccine 32: 355-362. http://dx.doi.org/10.1016/j.vaccine.2013.11.036.
40. Fries LF, Smith GE, Glenn GM. 2013. A recombinant viruslike particle influenza A (H7N9) vaccine. N. Engl. J. Med. 369:2564-2566. http://dx.doi.org/10.1056/NEJMc1313186.